ArticleFrontiers in oncology2026
Active surveillance or surgical resection? A survey of treatment strategies for low-risk papillary thyroid microcarcinoma in adults.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to investigate the clinical status of active monitoring [active surveillance (AS)] or surgical resection for adult low-risk papillary thyroid microcarcinoma (cT1aN0M0 PTMC) in the military and some local medical institutions in southern China. Methods: A questionnaire survey was conducted on the actual treatment mode of adult PTMC patients in the member institutions of the Southern Theater Command General Surgery Specialty Alliance. The respondents mainly included surgeons engaged in the surgical treatment of thyroid diseases. Results: A total of 36 medical institutions received replies, and the average annual volume of thyroid surgery in these institutions exceeded 100 cases. For suspicious nodules detected via ultrasound, routine fine-needle aspiration cytology (FNAC) for all suspicious nodules was recommended by six institutions (16.7%); nine (25.0%) performed FNAC only for nodules larger than 10 mm. After diagnosis, AS was recommended by six institutions (16.7%), immediate surgery was recommended by six institutions (16.7%), and 13 institutions (36.1%) left the treatment decision to the patient. For the AS protocol, 22 institutions recommended initial monitoring every 3 months, and 11 recommended every 6 months. When obvious clinical symptoms, new lymph node metastasis, or extrathyroidal invasion appeared, these institutions tended to convert from AS to surgery. During the continuous 3-month period selected by each institution from 2024 to 2025, among 474 PTMC patients, 228 (48.1%) underwent immediate surgery as initial treatment, 175 (36.9%) chose initial AS, and 63 (13.3%) received radiofrequency/microwave ablation. Of the 175 patients initially managed with AS, 49 (28.0% of the AS group) subsequently underwent surgery. Correlation analysis showed that the number of patients undergoing surgery was significantly higher in general surgery departments and in institutions with a larger number of thyroid surgeons (p < 0.05). At the same time, the number of patients receiving AS was significantly higher in tertiary hospitals (p < 0.05). Conclusion: Within our specialized alliance member institutions, more than one-third of low-risk PTMC patients have adopted AS as their management strategy. However, significant variability exists across medical institutions regarding the indications and implementation protocols for AS. To facilitate the broader and more standardized application of AS, it is essential to strengthen educational efforts directed at both clinicians and patients and to develop more refined, population-specific clinical guidelines or expert consensus for the management of low-risk PTMC in the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.